Loading organizations...
§ Private Profile · Stevenage, Herefordshire, United Kingdom
ReViral is a technology company.
ReViral was a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics, primarily targeting Respiratory Syncytial Virus (RSV). The company advanced a pipeline of first-in-class compounds, including its lead candidate, sisunatovir. This orally administered inhibitor was designed to specifically block the fusion of the RSV virus to host cells, representing a targeted approach to managing a prevalent infectious disease.
The company was founded in 2011 by Khattereh Ahmadi, driven by the insight that there was a significant unmet medical need for effective antiviral treatments, particularly for RSV, which causes substantial global morbidity. ReViral embarked on its mission to identify and develop small molecule inhibitors against key viral targets, aiming to provide new therapeutic options where few existed.
ReViral's focus was on patients affected by RSV, including infants, the elderly, and immunocompromised individuals who face severe health consequences from the infection. The company’s long-term vision was to enlarge the antiviral market and improve patient outcomes through the introduction of innovative therapies for viral diseases, ultimately contributing to broader efforts in combating infectious illnesses.
ReViral has raised $120.0M across 3 funding rounds.
ReViral has raised $120.0M in total across 3 funding rounds.
ReViral has raised $120.0M across 3 funding rounds. Most recently, it raised $44.0M Series C in August 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2020 | $44M Series C | Jason Zhou | Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston, Brace Pharma Capital, Green Sands Equity, NEW Leaf Venture Partners, Novo Holdings, Perceptive Advisors | Announced |
| Jul 1, 2018 | $55M Series B | Isaac Manke, Nanna Lüneborg | Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston, Brace Pharma Capital, Perceptive Advisors | Announced |
| Sep 1, 2015 | $21M Series A | — | Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston | Announced |
ReViral has raised $120.0M in total across 3 funding rounds.
ReViral's investors include Jason Zhou, Andera Partners, OrbiMed, Seroba Life Sciences, Heather Preston, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, Perceptive Advisors, Isaac Manke, Nanna Lüneborg.
ReViral is not a technology company—it is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics.[1][3] The premise of your query contains an inaccuracy that should be clarified before proceeding with the requested analysis.
ReViral is a biotechnology company dedicated to discovering and developing novel antiviral therapies, with an initial focus on respiratory syncytial virus (RSV) treatment.[1][3] The company addresses a significant unmet medical need: RSV represents a major health concern for children, the elderly, and immunocompromised patients, creating a substantial commercial opportunity.[1]
The company's lead product candidate is sisunatovir, an orally administered fusion inhibitor that has demonstrated significant activity in Phase 2 clinical studies.[1][2] Sisunatovir significantly reduced viral load in a Phase 2 RSV human challenge study in healthy adults and was being evaluated in Phase 2 clinical development in infants.[3] ReViral also maintains a second program targeting RSV replication through N-protein inhibition, with a lead candidate in Phase 1 clinical development.[3]
ReViral was founded a decade before 2022 (approximately 2012) by Dr. Ken Powell and Dr. Stuart Cockerill, both bringing deep antiviral expertise to the venture.[3] The company emerged from a clear scientific mission: to develop world-class therapies for RSV patients, a virus that had long represented an underserved therapeutic area.[3]
The company achieved significant validation through multiple funding rounds. In August 2020, ReViral closed a $44 million Series C financing led by CR-CP Life Science Fund, demonstrating strong investor confidence in its clinical programs and management team.[2] This capital supported Phase 2 clinical development for sisunatovir and advancement of the N-protein replication inhibitor program into Phase 1 trials.[2]
In April 2022, Pfizer acquired ReViral in a definitive agreement, recognizing the company's promising therapeutic candidates and deep antiviral expertise.[3] At the time of the announcement, Pfizer projected that ReViral's programs could generate annual revenue of $1.5 billion or more, underscoring the commercial potential of its RSV pipeline.[5] CEO Alex Sapir characterized Pfizer as "an optimal partner given their commitment to RSV," highlighting the strategic fit between the companies' missions.[5]
Following this acquisition, ReViral's development programs were integrated into Pfizer's broader portfolio, which now includes Abrysvo, an RSV vaccine approved in 2023 as part of Pfizer's competitive position in the RSV market alongside Moderna's mResvia and GSK's Arexvy.[5]